Penn’s one-stop solution for technology commercialization and entrepreneurship
I’m a Faculty Member or Researcher
I’m with a Company
I’m an Entrepreneur
I want to:
Translating Discoveries
PCI helps to translate discoveries and ideas created at the University of Pennsylvania into new products and businesses for societal benefit.
We actively facilitate a broad range of technology development connections between Penn and the private sector. Whether the end result is a technology license, an R&D alliance, or the formation of a new venture, PCI serves as a dedicated one-stop shop for commercial partnering with Penn.
Read the report hereInnovation Stories
Penn Faculty Receive ARPA-H Awards for Gene Therapy Research
The Advanced Research Projects Agency for Health (ARPA-H) awarded $43 million to Philadelphia gene therapy researchers to advance treatments for rare diseases. The recipients include:
- GEMMA Biotherapeutics, a Penn spinout co-founded by Jim Wilson, MD, PhD, emeritus professor in Penn Medicine, to develop gene therapies using AI.
- CHOP, to support a team led by Kiran Musunuru, MD, PhD, the Barry J. Gertz Professor for Translational Research at Penn Medicine, and Rebecca Ahrens-Nicklas, MD, PhD, Director of the Gene Therapy for Inherited Metabolic Disorders Frontier Program (GTIMD) at Children’s Hospital of Philadelphia, which is developing a platform for treating rare genetic, liver-related diseases in infants and children.
This funding will support the advancement and scaling of groundbreaking treatment opportunities for patients.
Learn MoreKira Pharmaceuticals to Merge with Jasper Therapeutics
Jasper Therapeutics recently completed its merger with Kira Pharmaceuticals, a startup company co-founded by Penn Medicine’s Wenchao Song, PhD, Professor of Systems Pharmacology and Translational Therapeutics at Penn Medicine. The combined company is focused on the development of biologic therapies for immune-mediated diseases, including complement pathway programs originating from Kira and the laboratory of Dr. Song. As part of the agreement, Kira out-licensed two complement-pathway assets to Mirador, which is expected to initiate clinical development later this year.
Learn More
Read the Latest News from PCI on LinkedIn
Available Technologies
Find technology opportunities by sector or search:
Nanotechnology | Antibody | Optics & Photonics | Medical Devices | COVID-19 | Immunology | Oncology | Materials | Bioengineering | Neurodegenerative Diseases
View all technologies
Upcoming Events
All Events